Frank O'Rourke (Kildare North, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

294. To ask the Minister for Health the policies he and his Department are pursuing to ensure that the drug Orkambi will be available for cystic fibrosis patients here; and if he will make a statement on the matter. [38375/16]

Simon Harris (Wicklow, Fine Gael)
Link to this: Individually | In context | Oireachtas source

The HSE has statutory responsibility for decisions on pricing and reimbursement of medicines in the community drugs schemes, in accordance with the Health (Pricing and Supply of Medical Goods) Act 2013.

In reaching its decision, the HSE examines all the evidence which may be relevant, in its view, for the decision (including the information/dossier submitted by the company) and will take into account such expert opinions and recommendations that it may have sought at its sole discretion (for example, from the National Centre for Pharmacoeconomics).

In considering an application, the HSE will also have regard to Part 1 and Part 3 of Schedule 3 of the 2013 Act. Part 3 requires the HSE to have regard to the following criteria:

- the health needs of the public;

- the cost-effectiveness of meeting health needs by supplying the item concerned rather than providing other health services;

- the availability and suitability of items for supply or reimbursement;

- the proposed costs, benefits and risks of the item or listed item relative to therapeutically similar items or listed items provided in other health service settings and the level of certainty in relation to the evidence of those costs, benefits and risks;

- the potential or actual budget impact of the item or listed item;

- the clinical need for the item or listed item;

- the appropriate level of clinical supervision required in relation to the item to ensure patient safety;

- the efficacy (performance in trial), effectiveness (performance in real situations) and added therapeutic benefit against existing standards of treatment (how much better it treats a condition than existing therapies); and

- the resources available to the HSE.

I am advised that, at the HSE’s request, the NCPE carried out an assessment of the manufacturer's economic dossier, submitted in March 2016, on the cost effectiveness of Orkambi. This dossier included details on all relevant costs and cost offsets, such as those associated with hospitalisation, disease management costs, intravenous antibiotics, adverse events and any additional costs arising in patients not taking Orkambi.

The NCPE has completed its health technology assessment. This was submitted to the HSE in June 2016 and is available on the NCPE website. The NCPE determined, following an evaluation of the economic dossier, that the manufacturer failed to demonstrate cost-effectiveness or value for money from using the drug. The NCPE has confirmed that all relevant costs were included in the analysis.

The HSE has recently completed its most recent round of negotiations with the manufacturer. On foot of this, the HSE’s Drugs Committee, having considered the NCPE recommendation and other expert advice, is in the process of sending its latest recommendation on the cost-effectiveness of Orkambi to the HSE Directorate. The HSE Directorate will then make a decision, taking into consideration the manufacturer’s latest price offer. This decision will be made on objective scientific and economic grounds, in line with the 2013 Act.

I share the HSE's disappointment that the manufacturer in this case has maintained a very high price in negotiations on the potential reimbursement of Orkambi for Irish patients.

I appreciate that this is a very stressful time for cystic fibrosis patients and their families. However, I want to assure them that I do not consider this to be the end of the process. I would strongly urge the manufacturer in this case to fundamentally reconsider its position and to table a pricing proposal that can facilitate the provision of Orkambi for Irish patients, at a price that represents value for money for the health service and the taxpayer.

I would also like to inform the Deputy that I have written to the Health Ministers in England, Scotland, Canada and Australia, asking them to collaborate to try and make progress on accessing Orkambi at a cost effective price for cystic fibrosis patients in each of their countries.